Lymphoplasmacytic lymphoma is an indolent non-Hodgkin lymphoma associated with monoclonal IgM production, and is also referred to as Waldenström macroglobulinemia. It typically presents as a slow-growing B-cell malignancy involving bone marrow and related lymphoid tissues.
AbbVie is testing venetoclax in a Phase 2 study for adults with relapsed or refractory Waldenström macroglobulinemia or lymphoplasmacytic lymphoma in Japan, aiming to expand the drug into rare blood cancers.
The FDA accepted a new drug application for tirabrutinib to treat relapsed or refractory primary central nervous system lymphoma, with a decision expected December 18, 2026. The application is supported by phase 2 trial data showing a 67% overall response rate.
The FDA has accepted a new drug application for tirabrutinib, a BTK inhibitor, for relapsed/refractory primary central nervous system lymphoma under the accelerated approval pathway. The regulatory agency set a PDUFA target action date of December 18, 2026.
The FDA has accepted for filing the New Drug Application for tirabrutinib under the accelerated approval pathway for relapsed or refractory primary central nervous system lymphoma, setting a PDUFA action date of December 18, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07592481 |
Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors |
NOT_YET_RECRUITING | NA |
| NCT07387471 |
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) |
RECRUITING | PHASE2 |
| NCT07249905 |
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07231952 |
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) |
RECRUITING | PHASE2 |
| NCT07173790 |
Watch and Wait or Worry and Wait in Indolent Lymphoma |
ENROLLING_BY_INVITATION | |
| NCT06986174 |
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia |
RECRUITING | PHASE2 |
| NCT06860880 |
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program |
RECRUITING | NA |
| NCT06636175 |
64Cu-LLP2A for Imaging Hematologic Malignancies |
RECRUITING | EARLY_PHASE1 |
| NCT06340737 |
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas |
RECRUITING | PHASE1 |
| NCT05544019 |
Study of SGR-1505 in Mature B-Cell Neoplasms |
RECRUITING | PHASE1 |
